Feed RDC.DE
RD
Redcare Pharmacy RDC.DE · XETRA
77.85 € +4.08% (+3.05 €)
Summary
37 / 100 · Bulios Score
Valuation 36Growth 94Profitability 6Quality 15Debt 39Stability 37
What speaks for it
- Revenue grew by 35% a year over the last 3 years.
- It bought back its own shares for 157.3M € in the last fiscal year, 10% of its market value.
- Analysts expect revenue to grow by 17% this fiscal year.
What to watch
- The company made a loss over the last 12 months.
- Repaying its net debt would take 4.1 years of operating profit.
- It passes only 2 of the 9 points of the Piotroski financial health test.
- It missed profit estimates 5 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (EUR)
2021202220232024202520262027
Diluted EPS (EUR)
2021202220232024202520262027
- Analyst estimate
Revenue grew by 25% a year over 5 years. Over the last 3 years it grew by 35% a year. For the next fiscal year analysts expect revenue to grow by 17%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of 42.0M €.
Profitability in detailIs it financially healthy?
Debt is a burdenCash and short-term investments 118.9M €
Debt 354.7M €
Free cash flow over 12 months -97.6M €
Over the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 1
- Hold 0
- Sell 0
No analyst has published a price target.
100% of the analysts recommend buying.
Analysts in detail